Turkovac

Turkovac is a COVID-19 vaccine developed by the Health Institutes of Turkey. It is an inactivated vaccine, which means it uses a non-infectious version of the virus to stimulate an immune response.

Development

The development of Turkovac began in 2020, in response to the global COVID-19 pandemic. The vaccine was developed by the Health Institutes of Turkey, a government-funded research organization. The development process involved inactivating the SARS-CoV-2 virus, which causes COVID-19, so that it could not cause disease but could still stimulate an immune response.

Clinical Trials

Turkovac has undergone clinical trials to assess its safety and efficacy. The Phase 1 and 2 trials involved a small number of participants and focused on safety and dosage. The Phase 3 trial, which began in 2021, involved a larger number of participants and focused on efficacy. The results of these trials have not yet been published in a peer-reviewed journal.

Efficacy

The efficacy of Turkovac is still being evaluated. Preliminary results from the Phase 3 trial suggest that the vaccine is effective at preventing COVID-19, but these results have not yet been peer-reviewed.

Side Effects

As with all vaccines, Turkovac can cause side effects. The most common side effects are mild and include pain at the injection site, fatigue, headache, muscle pain, and fever. Serious side effects are rare.

Distribution

Turkovac is currently being distributed in Turkey. The Health Institutes of Turkey has stated that it plans to make the vaccine available to other countries in the future.

See Also

• COVID-19 vaccine
• Inactivated vaccine
• SARS-CoV-2
• Clinical trial
• Health Institutes of Turkey

This article is a stub related to pharmacology. You can help WikiMD by expanding it!